<table>
<thead>
<tr>
<th>CONTENTS</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
</tr>
<tr>
<td>Included</td>
</tr>
<tr>
<td>Approval Letter</td>
</tr>
<tr>
<td>Tentative Approval Letter</td>
</tr>
<tr>
<td>Approvable Letter</td>
</tr>
<tr>
<td>Final Printed Labeling</td>
</tr>
<tr>
<td>Medical Review(s)</td>
</tr>
<tr>
<td>Chemistry Review(s)</td>
</tr>
<tr>
<td>EA/FONSI</td>
</tr>
<tr>
<td>Pharmacology Review(s)</td>
</tr>
<tr>
<td>Statistical Review(s)</td>
</tr>
<tr>
<td>Microbiology Review(s)</td>
</tr>
<tr>
<td>Clinical Pharmacology</td>
</tr>
<tr>
<td>Biopharmaceutics Review(s)</td>
</tr>
<tr>
<td>Bioequivalence Review(s)</td>
</tr>
<tr>
<td>Administrative Document(s)</td>
</tr>
<tr>
<td>Correspondence</td>
</tr>
</tbody>
</table>
CENTER FOR DRUG EVALUATION AND RESEARCH

Approval Package for:

Application Number: NDA 20387/S012

Trade Name: Hyzaar 50-12.5 and 100-25 mg Tablets

Generic Name: (losartan potassium)

Sponsor: Merck & Co., Inc.

Approval Date: June 9, 1999

INDICATION: Provides for redesigned physician sample cartons for Cozaar (losartan potassium) 50 mg Tablets and Hyzaar (losartan potassium/hydrochlorothiazide) 50-12.5 and 100-25 mg Tablets.
Application Number: NDA 20387/S012

APPROVAL LETTER
Merck & Co., Inc.
Attention: Jeffery R. White, M.D.
Sumneytown Pike, P.O. Box 4
BLA-20
West Point, PA 19486

Dear Dr. White:

Please refer to your supplemental new drug applications dated January 18, 1999, received January 25, 1999, submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act for Cozaar (losartan potassium) 25 and 50 mg Tablets (NDA 20-386), and Hyzaar (losartan potassium/hydrochlorothiazide) 50-12.5 and 100-25 mg Tablets (NDA 20-387).

We acknowledge receipt of your submissions dated May 10, 1999.

These supplemental applications provide for redesigned physician sample cartons for Cozaar (losartan potassium) 50 mg Tablets and Hyzaar (losartan potassium/hydrochlorothiazide) 50-12.5 and 100-25 mg Tablets.

We have completed the review of these supplemental applications and have concluded that adequate information has been presented to demonstrate that the drug products are safe and effective for use as recommended in the submitted final printed labeling (sample cartons submitted May 10, 1999). Accordingly, these supplemental applications are approved effective on the date of this letter.

We remind you that you must comply with the requirements for an approved NDA set forth under 21 CFR 314.80 and 314.81.

If you have any questions, please contact:

Ms. Zelda McDonald
Regulatory Health Project Manager
(301) 594-5333

Sincerely yours,

/\[Signature\]
Raymond J. Lipicky, M.D.
Director
Division of Cardio-Renal Drug Products
Office of Drug Evaluation I
Center for Drug Evaluation and Research
CENTER FOR DRUG EVALUATION AND RESEARCH

APPLICATION NUMBER: NDA 20387/S012

FINAL PRINTED LABELING
HYZAAR® 50/12.5

(LOSARTAN POTASSIUM-
HYDROCHLOROTHIAZIDE TABLETS)

Each tablet contains 50 mg losartan potassium and 12.5 mg hydrochlorothiazide.

USUAL ADULT DOSAGE:
See accompanying circular.

Package not child-resistant. Keep this and all drugs out of reach of children. Rx only

Manuf. for:
MERCK & CO., INC.
West Point, PA 19486 USA

by:
DuPont Pharma
Wilmington, DE 19880 USA

HYZAAR® 50/12.5

(LOSARTAN POTASSIUM-
HYDROCHLOROTHIAZIDE TABLETS)

67627

Lot

Exp.
CENTER FOR DRUG EVALUATION AND RESEARCH

APPLICATION NUMBER: NDA 20387/S012

APPROVABLE LETTER
Merck Research Laboratories
Attention: Jeffrey R. White, M.D.
Synneytown Pike, P.O. Box 4
BLA-25
West Point, PA 19486

Dear Dr. White:

Please refer to your supplemental new drug applications dated January 18, 1999, received January 25, 1999, submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act for Cozaar (losartan potassium) 25 and 50 mg Tablets (NDA 20-386) and Hyzaar (losartan potassium/hydrochlorothiazide) 50-12.5 and 100-25 mg Tablets (NDA 20-387).

These supplemental applications provide for draft sample cartons for Cozaar (losartan potassium) 50 mg Tablets and for Hyzaar (losartan potassium/hydrochlorothiazide) 50-12.5 and 100-25 mg Tablets.

We have completed the review of these applications and they are approvable. Before these applications may be approved, however, it will be necessary for you to submit final printed labeling (FPL) for the drug. The labeling should be identical in content to the sample cartons included in your January 18, 1999 submission.

In addition, all previous revisions as reflected in the most recently approved labeling must be included. To facilitate review of your submission, please provide a highlighted or marked-up copy that shows the changes that are being made.

Please submit 20 copies of the final printed labeling (to each application), ten of which are individually mounted on heavy weight paper or similar material.

If additional information relating to the safety or effectiveness of these drugs becomes available, revision of the labeling may be required.

Within 10 days after the date of this letter, you are required to amend the supplemental applications, notify us of your intent to file amendments, or follow one of your other options under 21 CFR 314.110. In the absence of any such action FDA may proceed to withdraw the applications. Any amendment should respond to all the deficiencies listed. We will not process a partial reply as a major amendment nor will the review clock be reactivated until all deficiencies have been addressed.
If you have any questions, please contact:

Ms. Kathleen Bongiovanni  
Regulatory Health Project Manager  
(301) 594-5334

Sincerely yours,

Raymond J. Lipicky, M.D.  
Director  
Division of Cardio-Renal Drug Products  
Office of Drug Evaluation I  
Center for Drug Evaluation and Research

cc: Archival NDAs 20-386, 20-387  
HFD-110/Div. Files  
HFD-95/DDMS  
DISTRICT OFFICE  
HFD-110/K.Bongiovanni  
sb/2/12/99;2/23/99  
Initialed by: R Mittal/2/15/99  
K Srinivasachar/2/16/99  
A Proakis/2/16/99  
C Resnick/2/18/99  
K Knudsen/2/21/99  
C Ganley/2/17/99  
G Buehler for N Morgenstern/2/22/99

filename: 20386s017ac.doc

APPROVABLE (AE)
CENTER FOR DRUG EVALUATION AND RESEARCH

APPLICATION NUMBER: NDA 20387/S012

ADMINISTRATIVE DOCUMENTS
CSO Review of Final Printed Carton Labeling
NDA 20-386/S-017
NDA 20-387/S-012

Date of Submissions: May 10, 1999
Date of Review: June 1, 1999
Applicant Name: Merck & Co., Inc.
Product Names: Cozaar (losartan potassium) 25 and 50 mg Tablets (NDA 20-386)
Hyzaar (losartan potassium/hydrochlorothiazide) 50-12.5 and 100-25 mg Tablets (NDA 20-387)

Evaluation:

These submissions provide for final-printed physician sample cartons for Cozaar (losartan potassium) 50 mg Tablets and Hyzaar (losartan potassium/hydrochlorothiazide) 50-12.5 and 100-25 mg Tablets. I have reviewed the cartons and found them to be, as was requested in the February 24, 1999 approvable letter for these supplements, identical to the draft sample cartons submitted on January 18, 1999.

Recommendation:

Since the submitted final-printed physician sample cartons are identical to the January 18, 1999 submitted draft physician sample cartons, as was requested in the February 24, 1999 approvable letter for these supplements, I recommend that the Division issue an approval letter for these supplements.

/Ś/
Colleen LoCicero, CSO

cc: orig NDA 20-386
orig NDA 20-387
HFD-110
HFD-110/LoCicero
HFD-110/SBenton
RHPM Review of Labeling

NDA:
20-386/SLR-017 Cozaar (losartan potassium) Tablets
20-387/SLR-012 Hyzaar (losartan potassium/hydrochlorothiazide) Tablets

Date of submissions: January 18, 1999
Date of receipt: January 25, 1999
Applicant: Merck Research Laboratories

Background: Merck has submitted these supplements to provide for sample cartons (complimentary, each containing one bottle of 7 tablets) for Cozaar (losartan potassium) 50 mg Tablets and Hyzaar (losartan potassium/hydrochlorothiazide) 50-12.5 and 100-25 mg Tablets.

Our approvable letter for NDA 20-387/S-008, dated August 10, 1998, included the following:

"Please delete [from the proprietary name] in the package insert and all carton and container labeling. The [is unnecessary and crowds an already cluttered abbreviation list. Listing the strengths (100/25) is adequate and succinctly provides a health-care practitioner with the essential information. Furthermore, by using [the product is tied to a reference strength that may at some future time not be available. Also, terms like [forte, and strong convey a therapeutic message of enhanced activity that may not be merited by the available data.

"Please delete the letters [from the logo on the carton and container labels for all strengths of Hyzaar. [has an established meaning for bioequivalence concerns as listed in the Orange Book, and its inclusion as part of a logo may render the labeling misleading."

Review: The three submitted draft sample cartons each include the proprietary and generic name, the tablet strength, the manufacturer, the sponsor, a place for lot number and expiration date, the storage statement, and the following statements:

- USUAL ADULT DOSAGE: See accompanying circular.
- Package not child-resistant. Keep this and all drugs out of reach of children.
- Cozaar or Hyzaar is a registered trademark of E.I. duPont de Nemours and Company, Wilmington, DE.
- Complimentary
- 1 Bottle of 7 Tablets
- Rx only
- Printed on Recycled Paperboard
  30% Post-Consumer Content

In addition, the Hyzaar cartons state either, “Each tablet contains 50 mg losartan potassium and 12.5 mg hydrochlorothiazide” or “Each tablet contains 100 mg losartan potassium and 25 mg hydrochlorothiazide.”

Merck has removed the __________ from to logo from all cartons as we requested in the August 10, 1998 approvable letter for NDA 20-387/S-008.

**Recommendation:** I will prepare an approvable letter for these supplements for Dr. Lipicky’s signature. These supplements ordinarily would fall under 21 CFR 314.70 (d). Changes described in the annual report, but since we asked for the revisions to the cartons, Merck submitted them in draft as labeling supplements.

\[\text{Signed}\]
Kathleen F. Bongiovanni

cc: NDA 20-386/S-017
    NDA 20-387/S-012
    HFD-110 (both)
    HF-2/MedWatch
    HFD-110/KBongiovanni
    HFD-110/SBenton

kb/2/11/99.
May 10, 1999

Raymond J. Lipicky, M.D., Director
Division of Cardio-Renal Drug Products
HFD-110, Room 16B-45
Office of Drug Evaluation I (CDER)
Food and Drug Administration
5600 Fishers Lane
Rockville, MD 20857

NDA 20-387/S-012: HYZAAR™ Tablets (Losartan Potassium/HCTZ)
Final Printed Labeling

Reference is made to the above referenced Supplemental New Drug Application dated January 18, 1999 and to the Agency’s Approvable letter dated February 24, 1999. This supplement provided for redesign of physician sample cartons for HYZAAR™ Tablets. Reference is also made to the Agency’s August 10, 1998 letter in which this redesign was requested. Included with this submission, as requested in the February 24, 1999 letter, are 20 copies of each of the final printed labeling.

Enclosed:

1. Sample Carton for 100-25 mg Tablet
2. Sample Carton for 50-12.5 mg Tablet

Questions concerning this supplement should be directed to Jeffery R. White, M.D., (610-397-3180) or, in my absence, to Larry P. Bell, M.D. (610-397-2310).

Sincerely,

Jeffery R. White, M.D.
Director, Regulatory Affairs

Enclosures
Certified No. P 967 685 399
March 31, 1999

Raymond J. Lipicky, M.D., Director
Division of Cardio-Renal Drug Products
HFD-110, Room 16B-45
Office of Drug Evaluation I (CDER)
Food and Drug Administration
5600 Fishers Lane
Rockville, MD 20857

NDA 20-386/S-017: COZAAR™ Tablets (Losartan Potassium)
NDA 20-387/S-012: HYZAAR™ Tablets (Losartan Potassium/HCTZ)

Intent To Amend


In accordance with 21 CFR 314.110, we wish to notify the Agency of our intent to file an amendment to this supplemental application.

Questions concerning this supplement should be directed to Jeffery R. White, M.D., (610-397-3180) or, in my absence, to Larry P. Bell, M.D. (610-397-2310).

Sincerely,

Jeffery R. White, M.D.
Director, Regulatory Affairs

Certified No. P 967 685 347

q1haf/mk954/int_amend
Dear Dr. Lipicky:

Pursuant to Section 505(b) of the Food, Drug and Cosmetic Act and in accordance with 21 CFR 314.70(c)(2), we submit a supplement to NDA 20-387 FOR APPROVAL. Reference is made to the Agency’s approvable letter for HYZAARTM 100-25 mg strength of August 10, 1998. In the August 10, 1998 approvable letter, the Agency requested deletion of from all carton and container labeling.

Reference is also made to the submission of September 11, 1998 in which final printed labeling, including a temporary 30 tablet unit of use HYZAARTM 100-25 physician sample, was provided. With the present submission, Merck is submitting redesigned physician sample cartons for both strengths of HYZAARTM. As requested, the have been removed from carton and container labeling.

As indicated on the attached Form FDA 356h, we are providing draft labeling for approval for HYZAARTM Tablets. This submission consists of draft labeling of sample carton for the 50-12.5 mg tablet (Tab 1) and sample carton for the 100-25 mg carton (Tab 2). In accordance with the Food and Drug Administration Modernization and Accountability Act of 1997, no fee is required for this supplemental application.
As required by Section 306(k)(1) of the Generic Drug Enforcement Act [21 U.S.C. 335a (k) (1)], we hereby certify that, in connection with this application, Merck & Co., Inc. did not and will not use in any capacity the services of any person debarred under subsections 306 (a) or (b) of the Act.

We consider the filing of this Supplemental New Drug Application to be a confidential matter, and request that the Food and Drug Administration not make its content, nor any future communications in regard to it, public without first obtaining the written permission of Merck & Co., Inc. Please direct questions or need for additional information to Jeffery R. White, M.D. (610/397-3180) or, in my absence, Larry P. Bell, M.D. (610/397-2310).

Sincerely,

Jeffery R. White, M.D.
Director, Regulatory Affairs

Attachments:  Mounted Proofs of Sample Cartons For the 50-12.5 mg Tablet
               Mounted Proofs of Sample Cartons For the 100-25 mg Tablet

Certified No:  P 967 671 287
Q:SELIGA/GINNY/LETTERS/20387DL